Silo Pharma files patent for ketamine implant therapeutic

Silo Pharma has filed a provisional patent application titled ‘Methods and Combinations for Managing Pain’ with the United States Patent and Trademark Office. The patent application includes protection for the Company’s SP-26 implantable drug delivery system for a novel time-released, dose-controlled formulation of ketamine, initially targeted for fibromyalgia. Silo believes that implantable drug delivery may be well-suited for chronic pain management. The next tests of the SP-26 ketamine implant will measure drug dissolution and time-release action.